BDX vs CTKB
BDX: BD is a leading global medical technology company providing essential medical devices, diagnostic systems, and laboratory solutions to healthcare providers and researchers worldwide. CTKB: Cytek Biosciences sells spectral flow cytometry instruments and integrated cell analysis platforms powered by patented Full Spectrum Profiling technology that enable high-resolution, high-dimensional single-cell analysis for biomedical research and clinical applications.
Side-by-side fundamentals
| Metric | BDX | CTKB | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $153.16 | $4.54 | |
| Market cap as of 2026-07-23 | $42.2B | $586M | |
| P/E as of 2026-07-23 | 37.10 | n/a | |
| PEG as of 2026-07-23 | -20.92 | -0.01 | BDX lower |
| Net margin as of 2026-07-23 | +5.3% | -36.3% | BDX higher |
| Gross margin as of 2026-07-23 | +47.0% | +51.7% | CTKB higher |
| Operating margin as of 2026-07-23 | +10.2% | -21.5% | BDX higher |
| ROE as of 2026-07-23 | +4.5% | -20.8% | BDX higher |
| ROA as of 2026-07-23 | +2.1% | -15.6% | BDX higher |
| Debt / equity as of 2026-07-23 | 0.72 | 0.03 | CTKB lower |
| Revenue growth (YoY) as of 2026-07-23 | +2.4% | +3.6% | CTKB higher |
| Revenue CAGR (3y) SEC XBRL | +5.0% | +7.1% | CTKB higher |
| Dividend yield as of 2026-07-23 | +2.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.21 | 1.17 | |
| 1-year return as of 2026-07-22 close | +7.5% | +47.4% | CTKB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.